PD Dr. Lothar Häberle

Department of Obstetrics and Gynaecology

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry (2026) Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial (2026) Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib (2026) Welslau M, Fasching P, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, et al. Journal article Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial (2026) Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, et al. Journal article Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer (2025) Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, et al. Journal article Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer (2025) Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, et al. Journal article The Epidemiology of Cervical Cancer in Germany: A Registry-Based Analysis of Incidence, Survival, and Tumor Characteristics (2003–2021) (2025) Stübs F, Beckmann M, Pöschke P, Heindl F, Emons J, Gaß P, Häberle L Journal article Adherence to digital pregnancy care – lessons learned from the SMART start feasibility study (2025) Jäger K, Nissen M, Leutheuser H, Danzberger N, Titzmann A, Pontones C, Goossens C, et al. Journal article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article